R&G PharmaStudies Co. Ltd. A (301333) — Free Cash Flow Generation Index
R&G PharmaStudies Co. Ltd. A (301333) has a Free Cash Flow Generation Index of 0.87x as of June 2022. Free cash flow of CN¥35.74 Million represents 1% of operating cash flow (CN¥40.98 Million). See working capital position of R&G PharmaStudies Co. Ltd. A to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
R&G PharmaStudies Co. Ltd. A Free Cash Flow Generation Index (2019–2025)
Historical FCF Generation Index trend for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Explore how well can R&G PharmaStudies Co. Ltd. A service its debt to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year Free Cash Flow Generation Index for R&G PharmaStudies Co. Ltd. A. For the full company profile including market capitalisation, see 301333 market cap overview.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.83x | CN¥94.93 Million | CN¥114.20 Million | CN¥19.28 Million | ▼ -4.6% |
| 2024 | 0.87x | CN¥134.78 Million | CN¥154.76 Million | CN¥19.98 Million | ▼ -2.9% |
| 2023 | 0.90x | CN¥172.68 Million | CN¥192.56 Million | CN¥19.88 Million | ▲ +6.7% |
| 2022 | 0.84x | CN¥109.64 Million | CN¥130.47 Million | CN¥20.83 Million | ▲ +26.2% |
| 2021 | 0.67x | CN¥76.29 Million | CN¥114.57 Million | CN¥38.28 Million | ▲ +57.7% |
| 2020 | 0.42x | CN¥18.62 Million | CN¥44.10 Million | CN¥25.48 Million | ▼ -43.6% |
| 2019 | 0.75x | CN¥77.47 Million | CN¥103.48 Million | CN¥26.00 Million | — |